02600nas a2200337 4500000000100000008004100001260001200042653001400054653001200068653001600080653002000096653002200116653001200138100001600150700001600166700001400182700001300196700001100209700001500220700001400235700001600249700001600265700001700281700001200298245010400310856008000414300000900494490000700503520173800510022001402248 2020 d c01/202010aM. leprae10aUCP-LFA10adiagnostics10ainnate immunity10alateral flow test10aleprosy1 avan Hooij A1 aTiĆ³-Coma M1 aVerhard E1 aKhatun M1 aAlam K1 aKon Fat ET1 ade Jong D1 aChowdhury A1 aCorstjens P1 aRichardus JH1 aGeluk A00aHousehold Contacts of Leprosy Patients in Endemic Areas Display a Specific Innate Immunity Profile. uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431626/pdf/fimmu-11-01811.pdf a18110 v113 a

Leprosy is a chronic infectious disease, caused by , that can lead to severe life-long disabilities. The transmission of is continuously ongoing as witnessed by the stable new case detection rate. The majority of exposed individuals does, however, not develop leprosy and is protected from infection by innate immune mechanisms. In this study the relation between innate immune markers and infection as well as the occurrence of leprosy was studied in household contacts (HCs) of leprosy patients with high bacillary loads. Serum proteins associated with innate immunity (ApoA1, CCL4, CRP, IL-1Ra, IL-6, IP-10, and S100A12) were determined by lateral flow assays (LFAs) in conjunction with the presence of DNA in nasal swabs (NS) and/or slit-skin smears (SSS). The HCs displayed ApoA1 and S100A12 levels similar to paucibacillary patients and could be differentiated from endemic controls based on the levels of these markers. In the 31 households included the number (percentage) of HCs that were concomitantly diagnosed with leprosy, or tested positive for DNA in NS and SSS, was not equally divided. Specifically, households where infection and leprosy disease was not observed amongst members of the household were characterized by higher S100A12 and lower CCL4 levels in whole blood assays of HCs in response to . Lateral flow assays provide a convenient diagnostic tool to quantitatively measure markers of the innate immune response and thereby detect individuals which are likely infected with and at risk of developing disease or transmitting bacteria. Low complexity diagnostic tests measuring innate immunity markers can therefore be applied to help identify who should be targeted for prophylactic treatment.

 a1664-3224